- Home
- AFRI vs NVCT Comparison
AFRI vs NVCT Comparison
Compare AFRI & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRI | NVCT |
|---|---|---|
| Founded | 1943 | 2020 |
| Country | Gibraltar | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.1M | 197.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AFRI | NVCT |
|---|---|---|
| Price | $11.03 | $8.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 23.8K | ★ 90.3K |
| Earning Date | 12-15-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,916,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.47 | $5.15 |
| 52 Week High | $11.42 | $11.52 |
Technical Indicators
Market Signals| Indicator | AFRI | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 66.49 |
| Support Level | $10.45 | $7.22 |
| Resistance Level | $11.42 | $7.91 |
| Average True Range (ATR) | 0.50 | 0.40 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 53.47 | 86.36 |
Price Performance
Historical ComparisonAbout AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.